The Centre Leon Berard Cancer Center

References

• Blay J Y, Bouhour D, Carrie C. The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no know cause of immunosuppression. Blood. 1995; 86: 2922–2929
   PubMed Web of Science ®Google Scholar
• Blay J Y, Burdin N, Rousset F. Serum IL-10 in non Hodgkin lymphoma: a prognostic factor. Blood. 1993; 82: 2169–2174
   PubMed Web of Science ®Google Scholar
• Blay J Y, Lasset C, Carrie C. Multivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma. A proposal for a prognostic scoring. Br J Cancer 1993; 67: 1136–1141
   Google Scholar
• Blay JY, Scheman S, Favrot M C. Local production of interleukin-6 by renal adenocarcinoma in vivo. J Natl Cancer inst. 1994; 86: 238
   PubMedGoogle Scholar
• Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429–431
   PubMed Web of Science ®Google Scholar
• Carrie C, Alapetite C, Mere P. Quality control or radiotherapeutic treatment of medulloblas-toma in a multicentric study. Radiother Oncol. 1992; 24: 77–81
   PubMed Web of Science ®Google Scholar
• Carrie C, Breteau N, Negrier S. The role of fast neuron therapy in unresectable pelvic osteosarcoma: preliminary report. Med Pediatr Oncol. 1994; 22: 355–357
   PubMedGoogle Scholar
• Carrie C, Lasset C, Alapetite C. Multivariate analysis of prognostic factors in adult patients with medulloblastoma. Retrospective study on 156 patients. Cancer 1994; 74: 2352–2360
   PubMed Web of Science ®Google Scholar
• Carrie C, Mottolese C, Bouffet E. Non-metastatic childhood ependymomas. Radiother Oncol. 1995; 36: 83–166
   Google Scholar
• Catimel G, Verweij J, Mattijssen V. Docetaxel (Taxoterer`): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol. 1994; 5: 533–537
   PubMed Web of Science ®Google Scholar
• Chauvin F, Souquet P J, Trillet-Lenoir V. Evaluation clinique et èconomique du bilan initial des cancers du poumon à petites cellules, alternatives à un bilan classique. Rev Mai Resp. 1993; 10: 445–451
   Google Scholar
• Chauvin F, Trillet V, Pour le G. L.O.T. (Groupe Lyonnais ďoncologie Thoracique). Pretreatment staging evaluation in SCLC. A new approach of medical decision making. Chest. 1992; 120: 497–502
   Google Scholar
• Combaret V, Gross N, Lasset C. Clinical relevance of CD44 cell surface expression and Nmyc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol. 1996; 14: 25–34
   Google Scholar
• Favrot M C, Combaret V, Lasset C. CD44: a new prognostic marker for neuroblastoma. N Engl J Med. 1993; 329: 1965
   Google Scholar
• Guastalla J P, Vermorken J B, Wils J A. Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy-a phase II study of the EORTC gynaecological cancer cooperative group. Eur J Cancer 1994; 30: 45–49
   Google Scholar
• Lasset C, Merrouche Y, Negrier S. Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinoma. Cancer Chemother Pharmacol. 1993; 32: 329–421
   Google Scholar
• Merrouche Y, Freyer G, Saltel P, Rebattu P. Quality of final care for terminal cancer patients in a comprehensive cancer center from the point of view of patients' families. Supportive Care in Cancer 1996; 4: 163–168
   Google Scholar
• Merrouche Y, Negrier S, Bain C. Clinical application of retroviral gene transfer in oncology: results of a French study with tumor infiltrating lymphocytes transduced with the gene of resistance to neomycin. J. Clin Oncol. 1995; 13: 410–418
   PubMed Web of Science ®Google Scholar
• Mornex F, Resbeut M, Richaud P. Radiotherapy and chemotherapy for invasive thymomas: a multicentric retrospective review of 90 cases. Int J Radial Oncol Biol Phys. 1995; 32: 651–659
   Google Scholar
• Négrier S, Lanier-Demma F, Lacroix-Kante V. Evaluation of the informed consent procedure in cancer patients candidate to immunotherapy. Eur J Cancer 1995; 31: 1650–1652
   Google Scholar
• Négrier S, Michon J, Floret D. Interleukin-2 lymphokine activated killer (LAK) cells in 15 children with advanced neuroblastoma. J Clin Oncol. 1991; 9: 1363–1370
   PubMed Web of Science ®Google Scholar
• Ozturk M, Bressac B, Puisieux A. p53 mutations in hepatocellular carcinoma after aflatoxin exposure. Lancet. 1991; 338: 1356–1359
   PubMed Web of Science ®Google Scholar
• Philip T, Chauvin F, Armitage J. PARMA international protocol: pilot study of DHAP followed by involved field radiotherapy and BEAC with autologous bone marrow transplantation. Blood. 1991; 77: 1587–1592
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non Hodgkin's lymphoma. N Engl J Med. 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Philip T, Hartmann O, Pinkerton R. Curability of relapsed childhood B cell non-Hodgkin's lymphoma after intensive first line therapy: a report from the Société Française d'Oncologie Pédiatrique. Blood. 1993; 81: 2003–2006
   PubMed Web of Science ®Google Scholar
• Philip T, Négrier S, Lasset C. Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study in 181 patients. Br J Cancer 1993; 68: 1036–1042
   Google Scholar
• Philip T, Zucker J M, Bernard J L. Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma over 1 year of age at diagnosis: is cure possible in a small subgroup. J. Clin Oncol. 1991; 9: 1037–1044
   PubMedGoogle Scholar
• Puisieux A, Galvin K, Troalen F. Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J. 1993; 7: 1407–1413
   PubMed Web of Science ®Google Scholar
• Puisieux A, Ji J, Guillot C. p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus. Proc Natl Acad Sci USA. 1995; 92: 1342–1346
   Google Scholar
• Rebattu P, Merrouche Y, Blay J Y, Martin C, Riou R, Perrin-Fayolle M. Phase II study of very high dose cisplatin in the treatment of malignant mesothelioma. Eur Respir Rev. 1993; 3: 226–228
   Google Scholar
• Rivoire M, Yoshida K, Divgi C, Welt S, Cohen A, Sigurdson E. Radioimmunodetection of hepatic metastases from human colon cancer in nude mice with a gamma-detecting probe. Cancer Res. 1990; 50: 877–879
   Google Scholar
• Souquet P J, Chauvin F, Boissel J P. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet. 1993; 342: 19–21
   PubMed Web of Science ®Google Scholar
• Unsal H, Yakicier C, Marcais C. Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci USA. 1994; 91: 822–826
   PubMed Web of Science ®Google Scholar
• Yoshida K, Rivoire M, Divgi C, Welt S, Sigurdson E. Radiolocalization of monoclonal antibodies in hepatic metastases from human colon cancer in congenitally athymic mice. Cancer Res. 1990; 50: 862–865
   Google Scholar